TrialAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).

James E Galvin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.